Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey. Show more

2 Headquarters Plaza, Morristown, NJ, 07960, United States

Biotechnology

Healthcare

Market Cap

201.3M

52 Wk Range

$1.57 - $5.50

Previous Close

$4.07

Open

$4.05

Volume

167,525

Day Range

$3.97 - $4.24

Enterprise Value

55.08M

Cash

123M

Avg Qtr Burn

-22.21M

Insider Ownership

13.75%

Institutional Own.

72.47%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HWK-016 (MUC16 Targeted ADC) Details Ovarian And Endometrial Cancers	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HWK-007 Details NSCLC, ovarian, endometrial cancers	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HWK-206 (Antibody-Drug Conjugate) Details Small-Cell Lung Cancer And Neuroendocrine Tumors	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.